A Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia

Sponsor
Wake Forest University Health Sciences (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05934851
Collaborator
Atrium Health Levine Cancer Institute (Other)
112
1
2
43
2.6

Study Details

Study Description

Brief Summary

The purpose of this study is to compare "Frozen-Section Directed Excision", which has been a proven method of surgery used in dermatology, versus the current, standard method called "Wide Local Excision" to treat high-grade vulvar dysplasia.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Frozen-Section Directed Excision
  • Procedure: Wide Local Excision
N/A

Detailed Description

This is a randomized, single-blinded study. The target population is adults ≥ 18 years of age with histological or cytological confirmation of VIN 2, VIN 3, VIN 2/3 or High-grade Dysplasia NOS with a planned excisional procedure, with high suspicion by the enrolling investigator that gross surgical margins of ≥ 3 mm can be achieved without laser or other destructive procedures. One group of subjects will be assigned to the Frozen-Section Directed Excision surgery arm and will undergo this procedure. The other group of subjects will be assigned to the Wide Local Excision (standard of care) arm and will undergo this procedure. The randomization will be 1:1, meaning for every subject who gets assigned to the Frozen-Section Directed Excision surgery arm, one will also be assigned to the Wide Local Excision arm. There is a 50% chance of getting randomized to either the Frozen-Section Directed Excision procedure or Wide Local Excision. Information regarding the surgery procedure, the amount of time the surgery procedure takes, and total amount of pain medication required during surgery and while in the surgery recovery area will be collected. The study team will also look at recurrence rates (return of the cancer) in six months, if any other therapies are required, and subject satisfaction related to the surgery, recovery, and sexual function by using questionnaires before and after the procedure.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
112 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Masking Description:
After randomization, the surgical assignment will be revealed to the attending surgeon. Subjects will remain blinded until the six-month post-operative study visit.
Primary Purpose:
Treatment
Official Title:
A Prospective, Randomized, Single-blinded Study Evaluating the Effect of Frozen-Section Directed Excision on Positive Surgical Margins in High-grade Vulvar Dysplasia
Anticipated Study Start Date :
Jul 31, 2023
Anticipated Primary Completion Date :
Aug 1, 2026
Anticipated Study Completion Date :
Mar 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Frozen-Section Directed Excision Vulvectomy

The surgeon(s) will identify the lesion and make a 1 mm excision around the lesion site.

Procedure: Frozen-Section Directed Excision
Frozen-Section Directed Excision (FSDE) is a surgical technique with evaluation of margin status during the surgical procedure, similar to the established Mohs Surgical Technique. The use of FSDE may ensure negative margins, decrease unnecessary excision of healthy tissue and has the potential to greatly reduce positive margins.
Other Names:
  • FSDE
  • Active Comparator: Wide Local Excision Vulvectomy

    The surgeon(s) will visually identify the abnormal lesion. A Wide Local Excision with 5 mm margins will be made through the dermis per standard of care.

    Procedure: Wide Local Excision
    Standard of care surgical technique utilized for VIN 2, VIN3, VIN 2/3 or High-grade Dysplasia NOS

    Outcome Measures

    Primary Outcome Measures

    1. Rates of positive margins for VIN 2, VIN 3, VIN 2/3 or High-grade Dysplasia NOS [At the time of the resection]

      Comparison of rates of positive margins for VIN 2, VIN 3, VIN 2/3 or High-grade Dysplasia NOS in subjects who undergo standard of care Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    Secondary Outcome Measures

    1. Recurrence rates at 6 months [6 months post resection surgery]

      Comparison of recurrence rates in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    2. Surgical time [At the time of the resection]

      Comparison of surgical time in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    3. Recovery room time [At the time of the resection and recovery]

      Comparison of recovery room time in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    4. Narcotic dose required (total during surgery and in recovery) [At the time of the resection and recovery]

      Comparison of narcotic dose required in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    5. Blood loss [At the time of the resection]

      Comparison of blood loss in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    6. Primary wound closure rates [2-week post resection surgery]

      Comparison of primary wound closure rates in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    7. Post-operative quality of life as determined by the SSQ-8 [2-weeks and 6 months after resection surgery]

      Comparison of post-operative quality of life as determined by the SSQ-8 in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    8. Sexual function as determined by the FSFI [Screening and 6 months after resection surgery]

      Comparison of sexual function as determined by the FSFI in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    9. Wound bed size after surgery [End of resection surgery]

      Comparison of wound bed size after surgery in subjects who undergo standard Wide Local Excision versus subjects who undergo Frozen-Section Directed Excision

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Written informed consent and HIPAA authorization for release of personal health information.

    2. Age ≥ 18 years at the time of consent

    3. Histological or cytological confirmation of VIN 2, VIN 3, VIN 2/3 or High-grade Dysplasia NOS with a planned excisional procedure, with high suspicion by the enrolling investigator that gross surgical margins of ≥ 3 mm can be achieved without laser or other destructive procedures

    4. Surgery is expected to occur within 90 days from randomization

    5. Ability to read and understand the English and/or Spanish language

    6. As determined by the enrolling physician, ability and willingness of the subject to comply with study procedures for the entire length of the study

    7. No known pregnancy

    Exclusion Criteria:
    1. Excision is not possible due to anatomy (proximity to urethra/clitoris)

    2. Known immunodeficiency syndrome

    3. Immunosuppressant medications taken within the last 30 days (HIV, organ transplant recipient, chronic steroid use/immunosuppressant)

    4. History of pelvic region radiation therapy

    5. Active anticancer treatment

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Levine Cancer Institute Charlotte North Carolina United States 28204

    Sponsors and Collaborators

    • Wake Forest University Health Sciences
    • Atrium Health Levine Cancer Institute

    Investigators

    • Principal Investigator: Robert W Naumann, MD, Wake Forest University Health Sciences

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Wake Forest University Health Sciences
    ClinicalTrials.gov Identifier:
    NCT05934851
    Other Study ID Numbers:
    • IRB00094930
    • LCI-GYN-VUL-FSDE-001
    First Posted:
    Jul 7, 2023
    Last Update Posted:
    Jul 7, 2023
    Last Verified:
    Jun 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 7, 2023